Sterilization Equipment Market Size & Share 2026-2035

Sterilization Equipment Market Size

The global sterilization equipment market was valued at USD 9.8 billion in 2025. The market is expected to grow from USD 10.5 billion in 2026 to USD 20.5 billion in 2035, growing at a CAGR of 7.8% during the forecast period, according to the latest report published by Global Market Insights Inc.

Demand is anchored in clinical and manufacturing requirements that cannot be deferred without creating infection-control, product-release, or regulatory exposure. Healthcare-associated infections reinforce this requirement: the World Health Organization estimates that 7 of every 100 hospitalized patients in high-income countries and 15 of every 100 in low- and middle-income countries acquire at least one healthcare-associated infection during care ^{[1]World Health Organization - The burden of health care-associated infection worldwide - who.int}. The CDC estimated approximately 518,000 healthcare-associated infections in U.S. hospitals during 2023, despite improvement from the prevalence measured in 2015 ^{[2]Centers for Disease Control and Prevention - New CDC Data Shows Decline in Healthcare-Associated Infections, 2026 - cdc.gov}. This burden keeps sterile processing investment tied to patient safety outcomes rather than solely to hospital capital-budget cycles.

Technology substitution is reshaping the addressable market. Steam remains the default option for instruments and process equipment that tolerate heat and moisture, while complex, heat-sensitive devices require low-temperature modalities. Ethylene oxide remains critical to the U.S. medical-device supply chain, but emissions controls and safety concerns are increasing the value of alternatives where device geometry and materials permit their use. The FDA's January 2024 recognition of vaporized hydrogen peroxide as an Established Category A sterilization method lowered a regulatory barrier for manufacturers and healthcare facilities evaluating hydrogen peroxide-based systems.

Recurring supplies materially alter the market's revenue profile. Indicators, sterile barrier systems, test packs, wraps, and reprocessing accessories are consumed with each validated cycle, creating demand that follows procedure volumes and manufacturing throughput rather than equipment replacement alone. This makes installed-base relationships, documentation capability, and consumable attachment central to supplier economics.

The transition will not be uniform. Hydrogen peroxide systems gain where short turnaround, low residual risk, and established regulatory acceptance matter most, but ethylene oxide retains a role for devices with challenging geometries and materials. Suppliers with multiple modalities, application-specific validation support, and recurring consumables are better positioned than single-product vendors because customers are unlikely to replace every legacy process with one alternative technology.

Key Drivers

Rising Incidence of Healthcare-Associated Infections

Healthcare-associated infections sustain demand for validated sterile processing because the cost of a failed process extends beyond equipment downtime to patient harm, infection-control intervention, and reputational risk. The CDC's 2023 survey found that pneumonia, surgical-site infections, and gastrointestinal infections were among the most common healthcare-associated infections in U.S. hospitals. Sterile processing departments therefore face continued pressure to document cycle performance and ensure reliable turnaround for surgical inventories.

The global burden is greater in resource-constrained systems, where intensive-care infection rates can be substantially higher than in general wards. WHO's 2024 infection-prevention analysis identifies structured infection-prevention and control programs as a practical means of reducing avoidable infections. WHO and OECD projections indicate that healthcare-associated infections could contribute to approximately 3.5 million deaths annually by 2050, while mortality is two to three times higher when infections involve antimicrobial-resistant pathogens. Sterilization equipment demand follows where hospitals move from isolated purchasing toward integrated reprocessing workflows that combine equipment, monitoring, staff procedures, and traceability.

Increasing Number of Surgical Procedures

Procedure growth raises both the number of instruments requiring reprocessing and the operational cost of equipment bottlenecks. The WHO surgical benchmark of 5,000 procedures per 100,000 population annually illustrates the scale of capacity expansion required in many health systems seeking to improve access to surgical care. New surgical capacity creates demand for core steam sterilization infrastructure, while greater procedure complexity raises the need for technology that can accommodate delicate and heat-sensitive instruments.

Minimally invasive, robotic, and endoscopic procedures change the mix of devices entering sterile processing departments. Fine optics, polymers, and long or narrow channels may not be compatible with conventional steam cycles. As a result, the driver is not simply higher unit volume; it also shifts procurement toward low-temperature systems, specialized accessories, and workflow designs that preserve instrument availability without compromising validated reprocessing.

Growing Pharmaceutical and Biotechnology Manufacturing

Biotech and pharmaceutical manufacturing requires contamination control throughout production, from preparation of process equipment through sterile filtration and fill-finish operations. The consequence of contamination can include batch rejection, production disruption, and patient-safety risk, making sterilization infrastructure integral to manufacturing quality systems rather than discretionary facility equipment.

This demand is especially relevant for biologics, injectables, vaccines, and other products that depend on aseptic processing. STERIS reported USD 5.5 billion in fiscal 2024 revenue, with 12% year-on-year growth and 10% constant-currency organic growth, reflecting continued demand across healthcare and life-sciences markets ^{[3]STERIS plc - Fiscal 2024 Fourth Quarter and Full Year Financial Results Press Release, May 8, 2024 - sterisplc.gcs-web.com}. Expansion of pharmaceutical manufacturing consequently supports several product categories at once: steam systems for process equipment, membrane filters for sensitive product streams, and low-temperature systems for isolators and specialized equipment.

Stringent Regulatory Requirements for Sterility Assurance

Regulatory updates are creating qualification and documentation work that often precedes equipment purchasing. The FDA's January 2024 final guidance for 510(k) submissions involving sterile devices clarified the review of sterility information and the classification of established sterilization methods ^{[4]U.S. Food and Drug Administration - Submission and Review of Sterility Information in Premarket Notification (510(k)) Submissions for Devices Labeled as Sterile, January 2024 - fda.gov}. Its accompanying recognition of vaporized hydrogen peroxide as an Established Category A method gives manufacturers a more defined route to support adoption of the technology.

European requirements are also raising the value of validated processes and documentation. Commission Implementing Decision (EU) 2024/817 updated references to harmonized standards for sterilization and packaging of terminally sterilized medical devices. EN 556-1:2024 sets requirements for devices designated as "STERILE". These changes increase the importance of suppliers that can support cycle development, process qualification, monitoring, and packaging validation rather than supplying equipment alone.

Key Restraints

Sterilization of Advanced Medical Instruments

The growing complexity of medical instruments limits the speed of technology substitution. Devices incorporating sensitive electronics, adhesives, advanced polymers, fine optics, or narrow internal channels may be damaged by heat and moisture, yet may also present diffusion challenges for certain low-temperature methods. This leaves many facilities operating multiple modalities in parallel rather than migrating rapidly from one platform to another.

Vaporized hydrogen peroxide provides a lower-residue alternative, but device compatibility remains application-specific. FDA materials on the method recognize limitations associated with particular device configurations. ASP's FDA-cleared ULTRA GI Cycle for duodenoscope reprocessing illustrates the engineering and validation work required to extend low-temperature sterilization to difficult applications. For buyers, the restraint translates into longer qualification cycles, broader validation requirements, and a continued need for specialized reprocessing pathways.

Adverse Effects of Chemical Disinfectants

Chemical sterilants create a complex trade-off between device compatibility, throughput, occupational safety, environmental compliance, and supply continuity. The EPA's March 2024 final rule for commercial ethylene oxide sterilizers required substantial emissions reductions across affected facilities. At the same time, the medical-device supply chain remains highly dependent on ethylene oxide for products that cannot readily shift to other methods.

European guidance further emphasizes risk assessment and quality-system controls for ethylene oxide use under the MDR and IVDR frameworks. The result is not an immediate elimination of chemical sterilization, but a higher cost of continued dependence. Commercial sterilizers may need to allocate capital to emissions abatement, documentation, and validation before expanding processing capacity, while device manufacturers must assess whether alternative methods are technically feasible for each product family.

Ethylene oxide's role will remain consequential because regulatory pressure does not remove the underlying compatibility advantage it offers for many devices. Near-term winners are likely to be suppliers and service providers that can support a mixed-modality environment, combining alternative technologies with validation expertise, emissions-compliance support, and disciplined documentation.

Sterilization Equipment Market Segment Analysis

By Product

Heat Sterilizers

Heat sterilizers generated approximately USD 2.4 billion in 2025. Steam autoclaves remain the principal solution for heat-stable surgical instruments, laboratory materials, and pharmaceutical process equipment because they provide established validation pathways, low per-cycle operating costs, and no toxic residue. Their role is reinforced by the expansion of hospital capacity, where central sterile supply departments require high-throughput systems with traceable cycle records.

Dry-heat systems serve narrower applications involving materials for which moisture is unsuitable, including certain powders, oils, glassware, and metal components. Their market role is more specialized, but they remain important in pharmaceutical quality-control and depyrogenation applications where steam is not appropriate.

Low-Temperature Sterilizers

Low-temperature sterilizers generated approximately USD 1.8 billion in 2025. Ethylene oxide remains important for complex and packaged devices, but its extended aeration requirements, emissions exposure, and regulatory scrutiny are changing the economics of new investment. Demand increasingly favors platforms that can offer shorter cycles and reduce toxicological or environmental exposure without sacrificing device compatibility.

Vaporized hydrogen peroxide is the principal alternative in hospital-based low-temperature sterilization. The FDA's Established Category A recognition improved its regulatory position, while the ULTRA GI Cycle clearance demonstrated that specialized system design can broaden use in endoscope reprocessing. Adoption will depend less on a universal replacement narrative than on whether specific device families can be validated for the modality.

Sterile Membrane Filters

Sterile membrane filters are critical to aseptic pharmaceutical processing because they permit sterilization of heat-sensitive liquid products without degrading sensitive active ingredients. Demand is linked to injectable biologics, vaccines, ophthalmic products, and other formulations that require controlled filtration as part of a validated aseptic process.

Unlike capital equipment, filters are consumed with production activity. This gives the segment exposure to biopharmaceutical manufacturing volumes and strengthens its relevance to contract development and manufacturing organizations that must maintain repeatable, documented contamination-control systems.

Radiation Sterilization Devices

Radiation sterilization supports high-volume processing of single-use and final-packaged medical devices. Gamma, electron-beam, and X-ray methods provide different combinations of penetration depth, throughput, and material compatibility. Their continuing importance reflects the scale of disposable medical-device production and the advantages of terminally sterilizing sealed products.

Contract sterilization remains an important route to market for device manufacturers that do not operate their own radiation infrastructure. STERIS reported Applied Sterilization Technologies fourth-quarter fiscal 2024 revenue of USD 250.9 million, up 5% year on year, although the company characterized organic growth as unusually low as demand normalized after earlier capacity constraints. That normalization highlights the value of diversified modality portfolios rather than dependence on a single processing method.

Consumables & Accessories

Consumables and accessories represented approximately 34.9% of market revenue in 2025 and are projected to exceed USD 7 billion by 2035 at approximately 7.6% CAGR. This category includes wraps, pouches, trays, biological and chemical indicators, test packs, tape, integrators, and endoscope accessories. Their recurring use ties revenue to sterilization cycles, surgical activity, and production throughput.

Packaging and indicator demand also reflects compliance needs. European standards referenced through Commission Implementing Decision (EU) 2024/817 include requirements relevant to packaging for terminally sterilized medical devices ^{[5]European Commission - Commission Implementing Decision (EU) 2024/817 of 6 March 2024 - eur-lex.europa.eu}. Suppliers that combine equipment with validated consumables and documentation can create a more durable installed-base relationship because changing one element of the workflow can require revalidation of the wider process.

By End Use

Hospitals & Clinics

Hospitals and clinics generated approximately USD 2.8 billion in 2025. Their demand centers on central sterile supply departments, operating rooms, endoscopy suites, and ambulatory settings where instrument availability directly affects procedure capacity. The continuing incidence of surgical-site infections and other healthcare-associated infections supports spending on reliable reprocessing workflows and traceability.

Hospitals increasingly evaluate equipment through workflow economics as well as capital cost. Rapid cycles, compact footprints, automated documentation, and service responsiveness can be decisive where instrument turnaround is a constraint on operating-room utilization.

Biotech & Pharma

Biotech and pharmaceutical companies accounted for approximately 31% of demand in 2025 and are projected to reach approximately USD 6.7 billion by 2035. These facilities require sterilization across process equipment, fill-finish lines, cleanroom materials, and product streams. Their demand is structurally linked to aseptic manufacturing requirements, which makes it less dependent on hospital procedure budgets.

The segment also supports multiple technologies simultaneously. Steam-in-place systems address process equipment, membrane filtration supports heat-sensitive products, and specialized low-temperature applications serve isolators and sensitive components. This breadth makes life-sciences customers strategically attractive to suppliers with integrated product and service portfolios.

Medical Device Companies

Medical-device companies generated approximately USD 2.3 billion in 2025. Their requirements are shaped by the need to validate finished-product sterilization before distribution, often for invasive, implantable, single-use, or sterile-packaged devices. Radiation and ethylene oxide remain significant at industrial scale because they can process packaged products and accommodate diverse material combinations.

The regulatory burden favors outsourced service providers for many manufacturers. A provider with access to multiple modalities can reduce the operational risk of relying on one method when new device designs, regulatory expectations, or supply-chain constraints change the appropriate sterilization route.

Food & Beverage

Food and beverage manufacturers use steam, thermal, and ultraviolet systems to control microbial risk in packaged products, food-contact equipment, and processing environments. Demand reflects food-safety requirements and the commercial value of shelf-life protection. The segment has different validation and throughput dynamics from healthcare, providing suppliers with an additional industrial demand base.

Other

Research laboratories, academic institutions, blood banks, veterinary facilities, and specialized industrial users represent a diversified market for autoclaves, dry-heat systems, and filtration equipment. Their purchasing volumes are smaller, but their requirements can be technically demanding where research productivity, biosafety, or validated laboratory practice depends on reliable sterilization capacity.

Biotech and pharmaceutical customers are particularly valuable because they combine recurrent filtration and consumable needs with capital requirements across several modalities. Hospitals remain indispensable, but their purchases are more exposed to budget timing and workflow constraints. Suppliers that can translate technical compatibility into validated, repeatable operating processes will have a stronger position than those competing primarily on equipment specifications.

Sterilization Equipment Market Regional Analysis

North America

North America was the largest regional market in 2025, accounting for approximately 35.8% of global revenue. The U.S. market generated approximately USD 3.2 billion in 2025. Its scale reflects a large installed base of hospitals, medical-device manufacturers, pharmaceutical facilities, and commercial sterilization operations.

Regulatory activity is a defining source of demand. The FDA's 2024 sterility guidance and recognition of vaporized hydrogen peroxide are supporting low-temperature qualification activity, while EPA requirements are increasing the compliance burden for ethylene oxide facilities ^{[6]U.S. Environmental Protection Agency - Final Amendments to Strengthen Air Toxics Standards for Ethylene Oxide Commercial Sterilizers, March 2024 - epa.gov}. North American customers consequently face simultaneous investment needs in equipment, validation, emissions management, and documentation.

Europe

Europe generated approximately USD 2.4 billion in 2025. Demand is strongly shaped by EU MDR and IVDR requirements, which make evidence of sterilization validation and sterile-barrier performance integral to medical-device market access. Commission Implementing Decision (EU) 2024/817 and EN 556-1:2024 reinforce the importance of current standards and defensible documentation.

The region's established hospital systems and medical-device manufacturing base support replacement demand, while scrutiny of ethylene oxide creates a preference for lower-emission alternatives where technically viable. European manufacturers and suppliers benefit where they can support compliance with both equipment performance and quality-management requirements.

Asia Pacific

Asia Pacific is forecast to be the fastest-growing regional market, with approximately 8.8% CAGR through 2035. Unlike mature markets, where demand is often tied to upgrades and technology replacement, much of Asia Pacific's opportunity comes from capacity additions in hospitals, laboratories, pharmaceutical plants, and medical-device facilities.

China's healthcare facility construction market, including infrastructure, digitalization, and medical equipment, exceeded USD 75 billion from 2020 to 2025, according to the International Trade Administration. The country has also expanded foreign-investment access in healthcare, with the first wholly foreign-owned tertiary general hospital receiving a business license in Tianjin in December 2024. These developments expand the addressable installed base for hospital-grade sterile processing equipment.

India presents a parallel expansion case. Leading private hospital chains were expected to add approximately 14,500 beds with capital expenditure of INR 30,000-32,000 crore by fiscal year 2027. Healthcare budget allocations increased by approximately 11% to INR 99,859 crore for FY2025-26. New capacity raises demand for basic steam sterilization infrastructure initially, with a later opportunity for higher-specification systems as surgical complexity and local life-sciences manufacturing increase.

Latin America

Latin American demand is concentrated in Brazil and Mexico, where hospital modernization, private-sector expansion, and growth in manufacturing support purchases of sterilization equipment and recurring supplies. The market is more exposed to currency volatility and public-budget constraints than North America or Europe, which can delay large capital purchases even when demand for infection-control capability remains clear.

Suppliers that offer dependable service coverage, modular equipment options, and consumable continuity are likely to be better suited to these operating conditions than those relying on infrequent large-system sales.

Middle East & Africa

The Middle East and Africa market has a split demand profile. Gulf Cooperation Council countries are expanding specialized healthcare infrastructure and pursuing internationally recognized care standards, creating opportunities for advanced hospital sterilization systems. Elsewhere, infrastructure gaps, import costs, and constrained healthcare budgets limit the pace of capital-equipment deployment.

The region therefore rewards adaptable commercial models. High-specification systems and service contracts can fit major Gulf projects, while durable, maintainable equipment and accessible consumables are more relevant in settings where technical support capacity and capital availability are constrained.

This distinction affects competitive strategy. Multinational suppliers can leverage regulatory expertise and premium low-temperature platforms in mature markets, while domestic and regional manufacturers can compete effectively where cost, local service, and installation speed determine initial adoption. The strongest portfolios will address both situations without assuming that a technology transition in developed markets will occur at the same pace in expanding healthcare systems.

Sterilization Equipment Market Share & Competitive Landscape

Competition is shaped by the ability to support a complete sterilization workflow rather than by equipment sales alone. Capital equipment suppliers compete on modality coverage, cycle performance, reliability, validation support, and service reach. Consumable suppliers benefit from recurring demand and from the switching costs associated with qualified indicators, packaging, and monitoring products. Regulatory change is increasing the importance of suppliers that can help customers document compliant processes while managing transitions between sterilization methods.

The competitive scope includes 3M Company, Advanced Sterilization Products (Fortive), Anderson Products, Belimed, Cardinal Health, Getinge, Matachana Group, Melag, Merck, MMM Group, Shinva Medical Instrument, STERIS, Stryker, Systec, and Tuttnauer.

3M Company

3M participates primarily through sterilization assurance products, including indicators, testing products, and sterile barrier materials. Its position is tied to the recurring need to verify cycle conditions and maintain documented evidence of process control.

Advanced Sterilization Products (Fortive)

Advanced Sterilization Products is focused on low-temperature hydrogen peroxide sterilization. Its STERRAD platform has expanded into more demanding endoscopy applications through the FDA-cleared ULTRA GI Cycle for duodenoscopes. The company's opportunity rests on combining equipment, proprietary consumables, and workflow support as hospitals seek alternatives for eligible heat-sensitive instruments.

Anderson Products

Anderson Products supplies chemical sterilants and high-level disinfection products for endoscope and heat-sensitive-device workflows. Its addressable market is influenced by the continued need for application-specific reprocessing solutions where full sterilization is not operationally or technically achievable with a single modality.

Belimed

Belimed provides washer-disinfectors, sterilizers, and process-management systems for hospital sterile processing departments and life-sciences facilities. Its integrated workflow positioning is relevant where customers seek to reduce manual handling and improve traceability across decontamination and sterilization steps.

Cardinal Health

Cardinal Health participates through distribution of infection-prevention supplies, sterile products, and related consumables. Distribution reach is strategically important in the consumables segment because hospitals require dependable replenishment for routine sterile processing.

Getinge

Getinge supplies steam and low-temperature sterilizers, washer-disinfectors, sterile transfer systems, and related services. The company reported 4.9% organic net sales growth in 2024, supported by performance in sterilizers and sterile-transfer products within Life Science ^{[7]Getinge AB - Year End Report 2024: Strong Order Intake and Increased Sales Contributed to Sharp Improvement in Margins, February 2025 - getinge.com}. Its broad portfolio supports customers that require coordinated solutions across hospital and life-sciences environments.

Matachana Group

Matachana Group serves healthcare and pharmaceutical users with sterilization, decontamination, and washer-disinfector equipment. Its position is supported by coverage across central sterile supply department workflows and specialized European applications.

Melag

Melag focuses on sterilization equipment for dental practices, dermatology clinics, and smaller surgical environments. Compact equipment, straightforward operation, and compliance documentation are important differentiators in these decentralized care settings.

Merck

Merck participates through sterile filtration membranes, microbiology products, and testing systems for pharmaceutical and biopharmaceutical production. The company's presence is most relevant to aseptic processing workflows where filtration is required for products that cannot tolerate terminal heat sterilization.

MMM Group

MMM Group provides steam sterilizers, low-temperature sterilizers, and washer-disinfectors for healthcare and pharmaceutical applications. Its product coverage supports demand for validated clinical and GMP-oriented sterilization processes.

Shinva Medical Instrument

Shinva Medical Instrument competes across steam, ethylene oxide, low-temperature plasma, and washer-disinfector equipment, with a strong domestic position in China. Its July 2025 LAS-M Series Vertical Autoclave launch extended its laboratory biosafety offering; the company stated that the first production batch of 20 units entered customer use following factory inspection. The launch illustrates how domestic suppliers can broaden their addressable market as regional laboratory and hospital capacity expands.

STERIS

STERIS serves healthcare, pharmaceutical, and industrial customers through capital equipment, consumables, and sterilization services. Fiscal 2024 revenue reached USD 5.5 billion, including 13% constant-currency organic growth in Healthcare. Its Applied Sterilization Technologies network offers multiple modalities, giving medical-device and pharmaceutical customers access to technology options without building each capability internally.

Stryker

Stryker participates through surgical-instrument reprocessing and sterile container systems used in hospital workflows. Its role is linked to the need to maintain compatibility between surgical instruments, sterile barriers, and central sterile supply department processes.

Systec

Systec specializes in laboratory and pharmaceutical-grade steam sterilizers. Its focus on validated process control supports research, biotechnology, and pharmaceutical customers requiring reliable sterilization of media, glassware, and laboratory consumables.

Tuttnauer

Tuttnauer offers tabletop and floor-standing autoclaves, washer-disinfectors, and accessories across medical, dental, veterinary, laboratory, and pharmaceutical applications. Its broad application coverage supports demand from both institutional and practice-based customers.

Recent Industry Developments

September 2025 - PENTAX Medical and ASP Launch Sterilizable DEC™ Duodenoscope in the United States

PENTAX Medical and Advanced Sterilization Products announced the U.S. launch of the Sterilizable DEC Duodenoscope on September 23, 2025. The product was commercially available from July 1, 2025, and is designed to enable sterilization of a reusable duodenoscope in 68 minutes using the STERRAD hydrogen peroxide system. The launch follows the FDA clearance of ASP's ULTRA GI Cycle and demonstrates the commercial relevance of adapting low-temperature sterilization to complex endoscopy applications.

July 2025 - Shinva Medical Instrument Launches LAS-M Series Vertical Autoclave

Shinva Medical Instrument introduced the LAS-M Series Vertical Autoclave in July 2025 for laboratory biosafety sterilization. The company identified improvements in durability, automation, cycle functionality, and operational consistency, and stated that an initial batch of 20 units entered active customer use following factory inspection.